Clinical Trial Update: Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia [Phase 3]

View source ↗

Summary

Phase 3 pediatric trial of tolvaptan (SAMSCA) for hyponatremia was terminated; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyponatremia

Drugs mentioned

• Samsca (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Hyponatremia | Phase 3 | Status: TERMINATED | Results posted: 2018-08-28